Review tracks the global footprint of Potomac horse fever agent
Bottom line
Potomac horse fever review maps a wider, still fragmented global picture
A new systematic review in Veterinary Research Communications pulls together the scattered literature on Neorickettsia risticii, the main cause of Potomac horse fever, and argues that the organism’s global distribution is broader and less neatly defined than many clinicians may assume. The review arrives alongside a 2026 Veterinary Microbiology paper describing equine neorickettsiosis as endemic in multiple regions of the United States and Canada, with recognized disease also reported in parts of Brazil and Uruguay. Current equine guidance from the American Association of Equine Practitioners, meanwhile, now frames Potomac horse fever as being caused by both N. risticii and Neorickettsia findlayensis, underscoring how the pathogen picture has evolved beyond the older single-agent view. (deepdyve.com)
Why it matters: For veterinary professionals, the practical message is that Potomac horse fever remains a surveillance and diagnostic challenge because ecology, geography, and pathogen diversity don’t line up cleanly with older teaching. Merck Veterinary Manual notes confirmed detection from clinical cases in a limited set of U.S. states, but also emphasizes the complex life cycle involving freshwater snails, trematodes, and aquatic insects, as well as the need for PCR-based confirmation from blood or feces. AAEP says cases are typically seasonal, often in summer and fall, and that horses in endemic areas are susceptible. A recent review also highlights that molecular testing is now the preferred diagnostic approach and that long-term prevention remains limited, in part because broadly protective vaccination has been difficult to achieve. (merckvetmanual.com)
What to watch: Expect more attention on geographic risk mapping, species-level diagnostics for N. risticii versus N. findlayensis, and whether newer molecular and genomic tools change how endemic areas are defined. (pmc.ncbi.nlm.nih.gov)
A newly published systematic review is trying to answer a deceptively simple question: where, exactly, is Neorickettsia risticii found? The answer matters because N. risticii is a key cause of Potomac horse fever, an acute, potentially fatal disease that still shows up unevenly across regions and seasons. The review, published March 18, 2026, in Veterinary Research Communications, synthesizes a literature base that has long been dispersed across countries, vectors, and host species. (deepdyve.com)
That timing is notable because the broader Potomac horse fever story has become more complex in recent years. A 2026 open-access review in Veterinary Microbiology says equine neorickettsiosis is caused by both N. risticii and N. findlayensis, and describes recognized endemic disease in multiple U.S. and Canadian regions, plus parts of Brazil and Uruguay. AAEP’s current disease guidance also reflects that two-species framing, rather than the older assumption that N. risticii alone explained Potomac horse fever cases. (sciencedirect.com)
The ecology helps explain why distribution has been hard to pin down. Neorickettsia organisms are maintained within digenean trematodes, and the transmission pathway involves freshwater snails and other hosts before horses are exposed, typically by ingesting infected aquatic insects. Merck Veterinary Manual says N. risticii has been identified in freshwater snails and trematodes, and its DNA has been detected in multiple aquatic insect groups, including caddisflies and mayflies. That means disease risk may depend as much on local water-associated ecosystems as on straightforward horse-to-horse epidemiology, which doesn’t occur because Potomac horse fever is considered non-contagious. (merckvetmanual.com)
Clinically, the disease is familiar but still easy to miss early. AAEP says signs can include high fever, anorexia, lethargy, diarrhea, laminitis, colic, edema, and abortion. Merck adds that diarrhea develops in about 60% of affected horses, while laminitis can complicate 20% to 30% of cases, and overall case fatality is reported at 5% to 30%. The newer Veterinary Microbiology review stresses that early antibiotic treatment improves prognosis, especially when clinicians treat presumptively in endemic areas before confirmatory results return. (aaep.org)
On diagnostics, recent literature points toward a more refined molecular approach. Merck says definitive diagnosis should rely on isolation or PCR detection from blood or feces, rather than serology alone. A 2023 diagnostic study from investigators at the Pennsylvania Veterinary Laboratory, Cornell, and the University of Kentucky reported that a duplex real-time PCR assay improved molecular detection and helped address false-positive concerns seen with fecal testing using a single 16S target alone. Separate work published in 2022 also described real-time PCR methods to differentiate N. findlayensis from N. risticii, a meaningful advance now that both organisms are recognized in Potomac horse fever. (merckvetmanual.com)
Industry and expert guidance has also stayed cautious on prevention. AAEP’s vaccination guidance says commercially available vaccines may not be fully protective, and Merck attributes field vaccine limitations in part to antigenic and genomic heterogeneity among strains. The 2026 global-perspective review reaches a similar conclusion, calling broadly protective, durable vaccines an ongoing research priority rather than a solved problem. For equine practitioners, that leaves environmental risk awareness, early recognition, and fast treatment as the main tools. (aaep.org)
Why it matters: This review is less about announcing a brand-new outbreak than about sharpening the map for a disease that may be underrecognized outside classic teaching zones. For veterinarians, the takeaway is to think in terms of ecology and diagnostic specificity, not just historical geography. A horse with fever, colitis, laminitis, or abortion risk near waterways during insect-heavy months may warrant Potomac horse fever on the differential even where the disease is considered uncommon, especially as published evidence grows from outside the traditional U.S. Mid-Atlantic narrative. That’s an inference from the assembled literature and current guidance, but it’s a practical one. (deepdyve.com)
What to watch: The next phase will likely center on better species-level surveillance, more standardized geographic reporting, and genomic work that links strain diversity to diagnostics and vaccine performance. If those pieces improve, endemic-area definitions, testing recommendations, and prevention strategies could all shift. (pubmed.ncbi.nlm.nih.gov)